Share

    


In This Section

Home / Blurb / Discussion List

FDA Approves Venetoclax for CLL, Small Lymphocytic Lymphoma

Jun 11, 2018, 16:58 PM
URL:

On June 8, 2018, the Food and Drug Administration (FDA) granted regular approval to venetoclax (Venclexta, AbbVie Inc. and Genentech Inc.) for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), with or without 17p deletion, who have received at least one prior therapy.

Read the full FDA announcement here.

Posted 6/11/2018

Leave a comment